![Josh Bilenker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 69 800 $ in data 30/06/2026
Joshua H.
Bilenker is the founder of Treeline Biosciences, Inc., founded in 2021, serving as Chief Executive Officer.
Dr. Bilenker was the founder of Loxo Oncology, Inc., founded in 2013, serving as President, Chief Executive Officer, CFO & Director from 2013 to 2015.
Dr. Bilenker is currently an Independent Director at Sana Biotechnology, Inc. since 2020.
Former positions include Director at LENSAR, Inc., Independent Non-Executive Director at ViewRay Technologies, Inc., Independent Director at Sorrento Tech, Inc. from 2012 to 2015, Independent Director at ViewRay, Inc. from 2008 to 2017, Director at BioEnterprise Corp., Independent Director at T2 Biosystems, Inc. from 2014 to 2017, Director at National Comprehensive Cancer Network Foundation, Independent Director at Gossamer Bio, Inc. from 2018 to 2023, Director at Roka Bioscience, Inc. from 2012 to 2015, Operating Partner at Aisling Capital LLC from 2006 to 2019, Chief Medical Officer at US Food & Drug Administration from 2004 to 2006, Board Observer at Aragon Pharmaceuticals, Inc., and Head-Loxo Oncology Research at Eli Lilly & Co. from 2019 to 2021.
Education includes an undergraduate degree from Princeton University conferred in 1994 and a doctorate from The Johns Hopkins University School of Medicine conferred in 1999.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 04/06/2026 | 20.000 ( 0,01% ) | 69 800 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Direttore/Membro del Consiglio | 01/12/2020 |
Treeline Biosciences, Inc.
 Treeline Biosciences, Inc. BiotechnologyHealth Technology Develops molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates for cancer, autoimmune and neurological diseases | Amministratore Delegato | 01/04/2021 |
| Società | Posizione | Fine |
|---|---|---|
| GOSSAMER BIO, INC. | Direttore/Membro del Consiglio | 08/06/2023 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2021 |
Aisling Capital LLC
 Aisling Capital LLC Investment ManagersFinance Aisling Capital invests in both private and public companies located in the Unites States. The firm targets companies operating in the fields of developing & commercializing important and innovative healthcare products, services & technologies sectors and industries. It provides financing for royalty deals, large cap leveraged buyout, seed, early and late stage capital requirements in the form of equity and debt. | Investitore di Private Equity | 01/12/2019 |
| LOXO ONCOLOGY INC | Amministratore Delegato | 01/02/2019 |
| VIEWRAY SYSTEMS, INC. | Direttore/Membro del Consiglio | 01/06/2017 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 18 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
LENSAR, Inc.
 LENSAR, Inc. Medical SpecialtiesHealth Technology Develops femtosecond laser technologies for refractive cataract surgery | Health Technology |
ViewRay Technologies, Inc.
 ViewRay Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Develops radiation therapy technology for the treatment of cancer | Commercial Services |
Aisling Capital LLC
Aisling Capital LLC Investment ManagersFinance Aisling Capital invests in both private and public companies located in the Unites States. The firm targets companies operating in the fields of developing & commercializing important and innovative healthcare products, services & technologies sectors and industries. It provides financing for royalty deals, large cap leveraged buyout, seed, early and late stage capital requirements in the form of equity and debt. | Finance |
Sorrento Tech, Inc.
 Sorrento Tech, Inc. Medical SpecialtiesHealth Technology Develops molecular assays and instrument systems for the food safety industry | Health Technology |
ViewRay, Inc.
 ViewRay, Inc. Medical SpecialtiesHealth Technology Designs, manufactures and markets the meridian radiation therapy system | Health Technology |
Princeton University
 Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment Operates agencies to protect health and human services | Government |
BioEnterprise Corp.
 BioEnterprise Corp. Miscellaneous Commercial ServicesCommercial Services Initiates for start up funding, and networking information, recruitment and emerging support firms | Commercial Services |
T2 Biosystems, Inc.
 T2 Biosystems, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and markets in-vitro diagnostic products | Health Technology |
Aragon Pharmaceuticals, Inc.
 Aragon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
National Comprehensive Cancer Network Foundation | |
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops medicine for cancer treatment | Health Technology |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gossamer Bio, Inc.
 Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Sana Biotechnology, Inc.
 Sana Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnological company which creates and delivers engineered cells as medicine for patients | Health Technology |
Roka Bioscience, Inc.
 Roka Bioscience, Inc. BiotechnologyHealth Technology Develops highly accurate molecular assays and instrument systems | Health Technology |
Treeline Biosciences, Inc.
Treeline Biosciences, Inc. BiotechnologyHealth Technology Develops molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates for cancer, autoimmune and neurological diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
